News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
389,303 Results
Type
Article (31477)
Company Profile (56)
Press Release (357770)
Section
Business (112569)
Career Advice (1314)
Deals (23995)
Drug Delivery (87)
Drug Development (59519)
Employer Resources (102)
FDA (9864)
Job Trends (9061)
News (211028)
Policy (25435)
Tag
Academia (1827)
Alliances (42022)
Alzheimer's disease (979)
Approvals (9800)
Artificial intelligence (88)
Bankruptcy (228)
Best Places to Work (7610)
Breast cancer (81)
Cancer (757)
Cardiovascular disease (54)
Career advice (1104)
Cell therapy (161)
Clinical research (46881)
Collaboration (287)
Compensation (151)
COVID-19 (2423)
Data (725)
Diabetes (118)
Diagnostics (3413)
Drug pricing (78)
Earnings (39301)
Employer resources (94)
Events (44516)
Executive appointments (118)
FDA (10216)
Funding (209)
Gene therapy (132)
GLP-1 (565)
Government (4012)
Healthcare (11356)
Infectious disease (2503)
Inflammatory bowel disease (63)
Interviews (228)
IPO (10305)
Job creations (1744)
Job search strategy (953)
Layoffs (248)
Legal (6994)
Lung cancer (122)
Manufacturing (127)
Medical device (5847)
Medtech (5848)
Mergers & acquisitions (13754)
Metabolic disorders (346)
Neuroscience (1175)
NextGen Class of 2024 (3651)
Non-profit (2757)
Northern California (884)
Obesity (211)
Opinion (170)
Parkinson's disease (59)
Patents (73)
People (24347)
Phase I (14131)
Phase II (20353)
Phase III (16523)
Pipeline (320)
Policy (64)
Postmarket research (1838)
Preclinical (5872)
Radiopharmaceuticals (194)
Rare diseases (147)
Real estate (2574)
Regulatory (15541)
Research institute (1586)
Resumes & cover letters (195)
Southern California (734)
Startups (1876)
United States (7278)
Vaccines (578)
Weight loss (177)
Date
Today (119)
Last 7 days (636)
Last 30 days (2266)
Last 365 days (22485)
2024 (20134)
2023 (25256)
2022 (33388)
2021 (35893)
2020 (34084)
2019 (27914)
2018 (21243)
2017 (20192)
2016 (18693)
2015 (21495)
2014 (15949)
2013 (12877)
2012 (13624)
2011 (14403)
2010 (13079)
Location
Africa (566)
Arizona (68)
Asia (25406)
Australia (4580)
California (1855)
Canada (744)
China (165)
Colorado (81)
Connecticut (74)
Europe (60935)
Florida (256)
Georgia (61)
Illinois (174)
Indiana (117)
Kansas (56)
Maryland (404)
Massachusetts (1347)
Michigan (70)
Minnesota (82)
New Jersey (584)
New York (605)
North Carolina (332)
Northern California (884)
Ohio (75)
Pennsylvania (455)
South America (794)
Southern California (734)
Texas (219)
Washington State (183)
389,303 Results for "octapharma ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Octapharma’s continuing dedication to improving the lives of people with rare bleeding disorders to be showcased at ISTH 2024
The most recent developments from Octapharma’s Haematology portfolio will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis on June 22–26, 2024, in Bangkok, Thailand.
June 10, 2024
·
9 min read
FDA
Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
Octapharma USA , Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older with von Willebrand disease (VWD).
April 29, 2024
·
4 min read
Business
Octapharma USA Appoints Biopharma Industry Veteran Kelly Hearn Vice President of Commercial Marketing & Development
Octapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as Vice President of Commercial Development & Marketing, assuming immediate leadership of the product marketing team as the company continues to grow its presence in the U.S. market.
May 20, 2024
·
2 min read
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Policy
Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures
Octapharma USA has announced Balfaxar® is now available. The new non-activated four factor prothrombin complex concentrate, approved by the U.S. FDA this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with need for urgent surgery or invasive procedures.
January 3, 2024
·
5 min read
Press Releases
Octapharma USA: JAMA Network Open Publishes Study Results Demonstrating Efficacy & Safety of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures
August 13, 2024
·
5 min read
Pharm Country
Octapharma USA: FDA Grants Expanded Approval to wilate® as the First VWF Concentrate for Prophylaxis in All Types of VWD
Octapharma USA announced the expansion of the U.S. Food and Drug Administration (FDA) approval for wilate ® , von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection.
December 5, 2023
·
5 min read
Press Releases
Octapharma USA Receives FDA Emergency Use Authorization for octaplasLG Powder, Allows U.S. Military Medical Providers Emergent Use in Treatment of Hemorrhage or Coagulopathy
August 20, 2024
·
8 min read
Pharm Country
Octapharma USA Presents Factor Concentrates for Perioperative Bleeding Symposium for ASA Annual Meeting Attendees
Octapharma USA will sponsor the scientific symposium, Factor Concentrates for Perioperative Bleeding – Global Perspectives, Sunday, October 15th in conjunction with the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco.
October 10, 2023
·
6 min read
1 of 38,931
Next